Abstract: A method is provided for sterilizing anthers of plants, such as Gramineae or Helianthus annuus (sunflower) by applying a sterilizing agent to the plants at the fifth and/or sixth stage of organogenesis, chosen from among terpenoid compounds of the methylcyclohexene series.
Type:
Grant
Filed:
November 1, 1989
Date of Patent:
April 23, 1991
Inventors:
Marat A. Fedin, Tatyana A. Kuznetsova, Viktor I. Lysenkov, Svetlana A. Novikova, Valentin A. Savchuk, Anatoly I. Sedelnikov, Vera P. Shabunya, Boris G. Udarov, Tatyana S. Tikhonova, Nina P. Polyakova, Sergei I. Paklin
Abstract: The use of a compound of formula (I) or a physiologically acceptable salt or hydrate thereof in the treatment, relief or prevention of the effects of cerebral ischaemia ##STR1## Compounds of formula (I) are described in UK Published Patent Application No. 2157691A.The compounds of formula (I) have been found to protect mammals, including man, against neuronal damage resulting from cerebral ischaemia.The preferred compound for use in this indication is (.+-.)-trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]-benzodioxino[2,3-c]- pyrrole (formula (I), R=H, R.sup.1 =F, R.sup.2 =H), especially in the form of its hydrochloride salt.
Abstract: Drug treatment therapies and kits for use therewith are disclosed. They involve the use of methimazole and/or its pro-drug carbimazole to reduce nephrotoxic effects of chemical exposure. In one embodiment, a patient receives cisplatin and then is treated with methimazole. The time delay in providing methimazole prevents the methimazole from being substantially expelled by the kidney prior to cisplatin reaching the kidney.
Abstract: A novel antimicrobial, aromatic and deodorizing agent composition and a method of reducing microbial concentration or inhibiting microbial growth using the composition are provided, which composition comprises a zeolote or porous glass carrier and a saturated monoterpene hydroperoxide as an active ingredient, the monoterpene hydroperoxide preferably selected from pinane hydroperoxide, thujane hydroperoxide, carane hydroperoxide, bornane hydroperoxide, paramenthane hydroperoxide, metamenthane hydroperoxide, and mixtures of the foregoing, etc.
Abstract: Androstane derivatives of the general Formula I ##STR1## in which R.sub.1 represents a hydrogen atom or a methyl group,X and Y each mean hydrogen atoms or together a carbon-carbon bond, andR.sub.2 symbolizes a hydrogen atom or an alkyl group with 1 to 6 carbon atoms,are pharmaceutically effective substances which have a distinct antiandrogenic effectiveness in topical application.
Type:
Grant
Filed:
July 13, 1989
Date of Patent:
April 23, 1991
Assignee:
Schering Aktiengesellschaft
Inventors:
Dieter Bittler, Henry Laurent, Petra Rach, Michael Topert
Abstract: An antioxidative biophylactic agent containing a substance that can induce metallothionein production in human or animal body. Manganese or compounds thereof, Streptococcus hemolyticus which has been deprived of a streptolysin-S-yielding ability, and an extract from coriolus versicolor belonging to the family Polyporaceae, Basidomycetes having a remarkable metallothinonein-inducing ability in vivo, and an antioxidative biophylactic effect such as radiation damage protection can be obtained by administering these metallothionein-inducing substances.
Abstract: This invention relates to the use of tenidap, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to inhibit activation of collagenase in a mammal and to inhibit the activity of myeloperoxidase in a mammal. This invention also relates to the use of tenidap and its salts for treating collagenase mediated disorders and diseases such as bone resorption disorders, corneal ulceration, periodontal disease, inflammatory disease and wounds of the skin and burns in mammals. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.
Type:
Grant
Filed:
March 19, 1990
Date of Patent:
April 16, 1991
Assignee:
Pfizer Inc.
Inventors:
Warren D. Blackburn, Jr., Leland D. Loose
Abstract: Compositions and methods for treating the symptoms of certain allergy-related conditions using capsaicin in solution or suspension combined with a selected local anesthetic, topical steroid or antihistamine. The same methods and compositions may be used to treat headaches.
Abstract: This invention concerns a method for using an ion exchange resin as a pharmaceutical for treating circulatory disturbances especially to aid in combating circulatory vessel constrictions or occlusions. An example of the method uses Resonium A resin.
Abstract: The invention provides compounds of the general formula (I) ##STR1## wherein X represents a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain andY represents a bond, or a C.sub.1-4 alkylene, C.sub.2-4 alkenylene or C.sub.2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8;Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups C.sub.1-3 alkyl, nitro, --(CH.sub.2)qR [where R is hydroxy, C.sub.1-3 alkoxy, --NR.sup.3 R.sup.4 (where R.sup.3 and R.sup.4 each represent a hydrogen atom, or a C.sub.1-4 alkyl group, or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--), --NR.sup.5 COR.sup.6 (where R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.
Type:
Grant
Filed:
May 15, 1990
Date of Patent:
April 9, 1991
Assignee:
Glaxo Group Limited
Inventors:
Ian F. Skidmore, Lawrence H. C. Lunts, Harry Finch, Alan Naylor, Ian B. Campbell
Abstract: This invention is a method of influencing voluntary food intake of patients receiving parenteral infusions, by adding branched-chain amino acids to the infusion solution. The branched-chain amino acid solution prevents total parenteral suppression of appetite and increases oral voluntary food intake. The branched-chain amino acid solution lowers the risk of regurgitation and aspiration in patients for uhm preoperative nutritional support and is an essential part of therapy.
Abstract: This invention relates to the use of tenidap, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to inhibit the release of elastase by neutrophils in a mammal. This invention also relates to the use of tenidap and its salts for treating elastase-mediated diseases and dysfunctions such as arteritis, proteinuria and pulmonary emphysema in mammals. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.
Abstract: The present invention provides (1) an agent for improving the reduced functions of organs caused by inhibited blood circulation, characterized by containing, as an effective component, an organogermanium compound represented by the formula (I) ##STR1## wherein R.sub.1 to R.sub.3 are each a hydrogen atom, a lower alkyl group such as methyl, ethyl or the like which may be the same or different, or a substituted or unsubstituted phenyl group, and X is a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ (Y is a metal such as sodium, potassium or the like, or a basic group-containing compound such as lysozyme, basic amino acid or the like), and (2) a method for improving the reduced functions of organs caused by inhibited blood circulation, characterized by administering, in need of such treatment, an effective amount of an organogermanium compound represented by the above formula (I).
Type:
Grant
Filed:
July 23, 1990
Date of Patent:
April 9, 1991
Assignee:
Asai Germanium Research Institute Co., Ltd.
Abstract: A method for the treatment of conditions associated with atherosclerosis in vertebrate animals, particularly man. A prolactin-inhibiting compound administered to the animal exhibiting the atherosclerotic conditions, in dosage sufficient to decrease the total plasma cholesterol and total triglyceride levels, will over a sufficient period of time suppress atherosclerosis and reduce lipid plaques in the walls of the blood vessels of the animal. Exemplary of prolactin-inhibiting compounds are the ergot-related drugs 2-bromo-alpha-ergocryptine, 6-methyl-8 beta-carbobenzyloxy-aminomethyl-10 alpha-ergoline, 1,6-dimethyl-8 beta-carbobenzyloxy-aminomethyl-10 alpha-ergoline, 8-acylaminoergolenes, ergocornine, 9,10-dihydroergocornine, and D-2-halo-6-alkyl-8-substituted ergolines.
Type:
Grant
Filed:
October 17, 1988
Date of Patent:
April 9, 1991
Assignee:
Louisiana State University
Inventors:
Albert H. Meier, Anthony H. Cincotta, Donn D. Martin
Abstract: Complete feeds or supplementary feeds for fattening pigs, piglets and poultry, which consist of or contain magnesium dipropionate, are proposed. The feeds have an antistress effect in the animals.
Abstract: Tributenyltin compounds containing double bonds at C-1 or C-3 or combinats thereof are synthesized from symmetrical tetrabutenyltins to offer a sufficient toxicity to function as a biocide or an antifoulant compound for ships' hulls and have an increased rate of degradation to be compatable with the environment.
Type:
Grant
Filed:
May 26, 1989
Date of Patent:
April 9, 1991
Assignee:
The United States of America as represented by the Secretary of the Navy
Abstract: The invention relates to an agent for the prophylaxis of cardiac infarcti and for the prevention or reinfarctions, and is characterized by the fact that said agent comprises a combination of magnesium amino dicarboxylic acid halides, basic magnesium amino dicarboxylic acid salts, and magnesium halides, singly or in combination, on the one hand, and acetylsalicylic acid, on the other hand, as well as conventional pharmaceutical carriers, diluents, and/or adjuvants, as required.
Type:
Grant
Filed:
May 1, 1989
Date of Patent:
April 9, 1991
Assignee:
Verla-Pharm Arzneimittelfabrik Apotheker H.J.V. Ehrlich GmbH & Co. KG.
Abstract: Ruminants are fed a water-insoluble polymer, which may be swollen (i.e. having absorbed water to form a gel) or unswollen. At least 0.04 kg of (swollen) polymers per day per 100 kg body weight is administered, and the polymer has not necessarily been used as a substrate for the preparation of feedstuff.Such methods are particularly advantageous when the animal is being fed on a diet causing acid conditions in the rumen, such as a diet of silage.A useful polymer is ammonium polyacrylate cross-linked by about 500 ppm methylene bisacrylamide ("MBA").The polymers enhance feed conversion rates and hence lower the effective cost of feeding the animals.
Type:
Grant
Filed:
March 11, 1987
Date of Patent:
April 2, 1991
Assignees:
Rene Pich, Hubert Issaurat, Barry A. Thompson
Abstract: Methods of antagonizing gastrin and/or cholecystokinin (CCK) with benzodiazepine analogs are disclosed, as well as related pharmaceutical compositions, which are useful in treating disorders of the gastrointestinal tract, central nervous system, and of the appetite.
Type:
Grant
Filed:
November 9, 1988
Date of Patent:
April 2, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Ben E. Evans, Mark G. Bock, Roger M. Freidinger
Abstract: Concentrated aqueous solutions of 1,2-benzisothiazolin-3-one are prepared by incorporating a buffering agent such that the pH of the solution is between about 3.0 and 7.0, and further adding a sufficient amount of glutaraldehyde such that a greater amount of such 1,2-benzisothiazolin-3-one is in solution than would be in solution if such glutaraldehyde were not present. Also disclosed is a synergistic biocidal composition comprising glutaraldehyde and 1,2-benzisothiazolin-3-one, as well as an aqueous-based industrial composition comprising such synergistic biocidal composition.
Type:
Grant
Filed:
April 20, 1989
Date of Patent:
April 2, 1991
Assignees:
Imperial Chemical Industries plc, ICI Americas Inc.